AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20071293
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy with gemcitabine and cisplatin
Trial: 14585937
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (continuous intravenous infusion)
Trial: 9793283
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment modalities
Trial: 21542988
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) treated group
Trial: 18711765
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine therapy (TCM)
Trial: 15170148
Drug: Post-chemotherapy assessment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy assessment
Trial: 22585232
Drug: THC 15
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC 15 mg
Trial: 7633988
Drug: Intravenous pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentoxifylline infusion therapy, 600 mg twice daily for up to 21 days
Trial: 6404377
Drug: Bedtime administration
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime administration of intermediate acting insulin
Trial: 26810282
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with HDM allergen extract
Trial: 7000089
Drug: Colestipol hydrochloride
RxNorm normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colestipol hydrochloride (5 g X 3)
Trial: 24297946
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/day
Trial: 17399871
Drug: Trapeziectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapeziectomy with flexor carpi radialis suspension
Trial: 17464604
Drug: Infiltration around
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration around the hip joint with a mixture of 100 mL ropivacaine 2 mg/mL, 1 mL ketorolac 30 mg/mL, and 1 mL epinephrine 0.5 mg/mL (group A)
Trial: 11409559
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of bupivacaine 0.5% with epinephrine 0.0005%
Trial: 15114087
Drug: Alemtuzumab (Campath-1H)
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab (Campath-1H) and low-dose Tacrolimus (Tac)
Trial: 31686255
Drug: High-power therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-power therapeutic ultrasound with 5% lipolytic active caffeine gel (phonophoresis)
Trial: 21779579
Drug: 133 mg
RxNorm normalized name: glycine 133 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 133 mg caffeine
Trial: 9265993
Drug: Low hypnotic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hypnotic susceptible subjects
Trial: 17443649
Drug: nab-paclitaxel 10
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 10 mg/m2
Trial: 17443649
Drug: nab-paclitaxel 30
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 30 mg/m2
Trial: 25886254
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg modified-release capsules for 12 months
Trial: 10755239
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg/week
Trial: 24656609
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group)
Trial: 15094269
Drug: Nevirapine 400
RxNorm normalized name: nevirapine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 400 mg once daily
Trial: 15094269
Drug: Nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg twice daily
Trial: 24342768
Drug: Intravenous application
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous application of 50 μg CCK-4
Trial: 27090218
Drug: Sardine-enriched diet
RxNorm normalized name: sardine allergenic extract
DrugBank: European pilchard (DB10622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sardine-enriched diet (100 g of sardines 5 days a week for 6 months)
Trial: 772669
Drug: Triprolidine 2.5
RxNorm normalized name: triprolidine 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine 2.5 mg
Trial: 2894219
Drug: Dipipanone 8
RxNorm normalized name: dipipanone
DrugBank: Dipipanone (DB01491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipipanone 8 mg
Trial: 2100659
Drug: Cathode Iontophoresis
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathode Iontophoresis using Sodium Fluoride solution (2%)
Trial: 23978944
Drug: G-CSF post-chemotherapy
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF post-chemotherapy
Trial: 26840038
Drug: Low fasting
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fasting blood glucose (<70 mg/dL)
Trial: 10547245
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of OspA vaccine
Trial: 9293831
Drug: Transfusions to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusions to maintain hemoglobin level of 10 g/dL
Trial: 8984939
Drug: 240 U
RxNorm normalized name: tyrothricin 240 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 U kg‐1 r‐hu‐Epo subcutaneously, initially three doses weekly
Trial: 23051883
Drug: Ultraport zero
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultraport zero stopcock without hub disinfection before injection
Trial: 2688531
Drug: Ioxaglate 320
RxNorm normalized name: ioxaglate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate 320 mgI/ml
Trial: 28481050
Drug: Bifocal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifocal treatment of myopia (3-year duration)
Trial: 19650932
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg
Trial: 14980929
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg orally (DiazG)
Trial: 14980929
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 microg intrathecally (Clon(i/t)G)
Trial: 14980929
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 microg orally (Clon(p/o)G)
Trial: 31044654
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy (AT)
Trial: 9773865
Drug: Daily ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily ganciclovir
Trial: 9773865
Drug: 3-times-weekly ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-times-weekly ganciclovir
Trial: 30721234
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention comprising clinical guidelines, monthly prescribing review meetings, doctor‐patient communication skills training, and education materials for caregivers.
Trial: 25130768
Drug: Hot moisturizing
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot moisturizing formulation
Trial: 21375092
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron (2 ml, 4 mg)
Trial: 16816554
Drug: Apricitabine 400
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apricitabine 400 mg/day
Trial: 11564594
Drug: Subcutaneous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-2 at either 4.5 MIU or 7.5 MIU q12h for 5 days every 8 weeks
Trial: 9784909
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of propionyl-L-carnitine (IV bolus, 30 mg/kg body weight)
Trial: 29655624
Drug: Routine immunizations
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine immunizations (DTwP-HepB-Hib, oral polio, pneumococcal conjugate 7 vaccines)
Trial: 9415234
Drug: Topical 5-aminolaevulinic
RxNorm normalized name: methyl 5-aminolevulinate Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolaevulinic acid photodynamic therapy
Trial: 23669304
Drug: Antacid (Antagel)
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid (Antagel)
Trial: 19114704
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg every 2 weeks
Trial: 19262464
Drug: Prescription label
RxNorm normalized name: Last Refill For This Prescription Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription label reading skills
Trial: 31435005
Drug: Increased urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased urinary phosphorus excretion
Trial: 21301812
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg hydrocortisone
Trial: 21301812
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg hydrocortisone
Trial: 16612708
Drug: Vasopressin injections
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin injections (10 pmol/kg bw)
Trial: 7564362
Drug: Piretanide monotherapy
RxNorm normalized name: piretanide
DrugBank: Piretanide (DB02925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide monotherapy
Trial: 23645323
Drug: Ramipril monotherapy
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril monotherapy
Trial: 15453924
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70)
Trial: 10829313
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy combined with surgery
Trial: 29221491
Drug: Gantenerumab 105
RxNorm normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab 105 mg
Trial: 16237479
Drug: Cannabinoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabinoid therapy
Trial: 6837336
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion (1.75 g/kg within 3 hours)
Trial: 17954367
Drug: Olmesartan 10
RxNorm normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 10 mg/day
Trial: 19714275
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with modified Hagie pin
Trial: 15008768
Drug: Incremental infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental infusion of oxytocin discontinued at 5 cm dilation (Group B)
Trial: 7724111
Drug: Oral sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulindac (200 mg, once orally every 12 hours for 7 days)
Trial: 2684077
Drug: methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone acetate (20 mg) intrabursal injection and oral naproxen (1 g/d for 10 days)
Trial: 2684077
Drug: methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone acetate (20 mg) intrabursal injection and oral placebo for 10 days
Trial: 30698725
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) 0 g protein
Trial: 29277353
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (PHiD-CV 4-dose and 1-dose)
Trial: 8966494
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplements (1.2 g of calcium and 800 IU of vitamin D3)
Trial: 30845291
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + Amoxicillin + Metronidazole, each 500 mg, three times daily, for seven days (test group)
Trial: 25573533
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2)
Trial: 9688014
Drug: Continuous fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous fluconazole at 200 mg/day
Trial: 7805084
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody inhibitors to platelet membrane glycoprotein IIb/IIIa
Trial: 31950948
Drug: GTE-CUR drink
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GTE-CUR drink (17.3 and 35.5 mg EGCG equivalent)
Trial: 6846738
Drug: Budesonide treatment
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide treatment for 1 week
Trial: 31487573
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) delivered as therapist-guided bibliotherapy
Trial: 21982325
Drug: Water-based exercise
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based exercise program (12 weeks, twice weekly)
Trial: 19297572
Drug: CMV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV vaccine
Trial: 19082528
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (calcium supplement plus menatetrenone)
Trial: 26165528
Drug: Non-rebreather mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-rebreather mask (NRB) at 10 L·min⁻¹
Trial: 18182467
Drug: PE +
RxNorm normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE + F (oral fludrocortisone, 0.2 mg)
Trial: 2692971
Drug: Naftifine (1%)
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine (1%) spray
Trial: 15930418
Drug: Zoster vaccine
RxNorm normalized name: ZOSTER VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoster vaccine
Trial: 9266790
Drug: Intravenous dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dipyridamole infusion (0.56 mg/kg over a 4‐minute period) 48 to 96 hours after onset of symptoms
Trial: 6384073
Drug: Indoprofen 400
RxNorm normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indoprofen 400 mg
Trial: 10194770
Drug: HIV myelitis
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV myelitis in drug users (17%)
Trial: 6990675
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg the night before and 400 mg on the morning of surgery
Trial: 19092349
Drug: Methylprednisolone treatment
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone treatment
Trial: 28235531
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose (0.5mg/kg) of propofol with divided remifentanil injections and moderate hyperventilation (ETCO2 of 30‐35mmHg) (group RP/H)
Trial: 24524031
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg
Trial: 2611360
Drug: Flurbiprofen without
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen without Maalox (antacid)
Trial: 25344393
Drug: TEAMS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAMS therapy
Trial: 8253920
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone
Trial: 9373732
Drug: IFN alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN alpha-2b (3 x 10(6) IU, 3 times weekly)
Trial: 24925985
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (paroxetine)
Trial: 18977955
Drug: RIX4414 administered
RxNorm normalized name: HUMAN ROTAVIRUS A TYPE G1P(8) STRAIN RIX4414 LIVE ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 administered separately at 3 and 5 months
Trial: 15358571
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-treated area for topical CS application).
Trial: 3054280
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of acarbose treatment
Trial: 8679790
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg TRH intravenously 20 min before ECT
Trial: 27486878
Drug: PF induction
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF induction chemotherapy (cisplatin and fluorouracil)
Trial: 19097665
Drug: Sitagliptin 100mg
RxNorm normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100mg once daily
Trial: 22030199
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 1 mL of lidocaine gel 2% (control)
Trial: 15029476
Drug: Good common
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good common practice drugs
Trial: 9223201
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine and 1 mg preservative-free morphine (group BUP-MORPH)
Trial: 9223201
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL normal saline with 1:200,000 epinephrine and 1 mg preservative-free morphine (group MORPH)
Trial: 31945074
Drug: Weekly training
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly training interval